The Pfizer and Takeda-backed breast cancer therapy developer has filed to raise $75m in an initial public offering that follows some $130m in equity financing.
US-based antibody drug conjugate (ADC) developer Mersana Therapeutics has filed for a $75m initial public offering that will give exits to pharmaceutical firms Takeda and Pfizer.
Mersana is working on ADC therapies for cancer and the IPO proceeds will fund a phase 1 clinical trial for its lead drug candidate, a breast cancer treatment called XMT-1522. The capital will also support preclinical and phase 1 trials for a second candidate, XMT-1536.
The company has raised approximately $130m in equity financing,…
